Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a serious problem in Japan. Omalizumab, a humanized monoclonal anti-IgE antibody, improves symptoms associated with SAR, but a study comprehensively investigating the clinical efficacy, safety and pharmacological effects of omalizumab re-treatment has not yet been conducted.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Int. Arch. Allergy Immunol.

Title: International archives of allergy and immunology

Publisher: S. Karger AG

ISSN (Electronic): 1423-0097

ISSN (Print): 1018-2438

Publication date (Electronic): 2009

Volume: 149

Issue: 3

Affiliations

[1 ] Graduate School of Allied Health Science, Faculty of Medicine, Osaka University, Suita-shi, Osaka, Japan. ogino@sahs.med.osaka-u.ac.jp

Article

Publisher Item ID: 000199719

DOI: 10.1159/000199719

PubMed ID: 19218816

SO-VID: ff2eaa42-929b-4854-a050-770a98a381b2

History

Data availability:

Comments

Comment on this article

scite_

0

Smart Citations

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 6

See all cited by